Enliven Therapeutics financials
$46.51+1.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$119.7M | -$104.6M | -$83.5M |
| Net income | -$103.7M | -$89.0M | -$71.6M |
| Net margin | — | — | — |
| Diluted EPS | $-1.83 | $-1.89 | $-2.01 |
| EBITDA | -$119.4M | -$104.2M | -$83.2M |
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M |
| Free cash flow | -$70.5M | -$73.2M | -$61.4M |
| Diluted shares | 56.7M | 47.1M | 35.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $98.9M | $124.1M | $100.1M |
| Short-term investments | $363.7M | $189.3M | $153.0M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $476.2M | $325.8M | $271.9M |
| Total liabilities | $16.6M | $15.9M | $26.0M |
| Shareholders' equity | $459.6M | $309.8M | $245.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology